{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T22:41:01Z","timestamp":1792536061610,"version":"4.5.0"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020956","name":"Merck Healthcare KGaA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020956","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003852","name":"Regione Campania","doi-asserted-by":"publisher","award":["Cup 21C17000030007"],"award-info":[{"award-number":["Cup 21C17000030007"]}],"id":[{"id":"10.13039\/501100003852","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009945","name":"Merck KGaA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009945","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmogastro.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Gastrointestinal Oncology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.esmogo.2026.100398","type":"journal-article","created":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T17:52:42Z","timestamp":1786384362000},"page":"100398","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"PB","title":["Predictive biomarkers for cetuximab-based rechallenge therapy in metastatic colorectal cancer: a pooled analysis of the CAVE and CAVE-2 GOIM studies"],"prefix":"10.1016","volume":"13","author":[{"given":"D.","family":"Ciardiello","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Martini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Pietrantonio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Avallone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Pisconti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Santabarbara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.P.","family":"Latiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Tortora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0780-0409","authenticated-orcid":false,"given":"A.","family":"Sartore-Bianchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Cremolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Messina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.G.","family":"Zampino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2313-2247","authenticated-orcid":false,"given":"L.","family":"Foltran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3159-5268","authenticated-orcid":false,"given":"C.","family":"Pinto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Zaniboni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Antonuzzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Normanno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Berardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5852-1509","authenticated-orcid":false,"given":"A.","family":"Cogoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7999-9739","authenticated-orcid":false,"given":"C.","family":"Lotesoriere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Bordonaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1026-3923","authenticated-orcid":false,"given":"L.","family":"Boscolo Bielo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Curigliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3813-6339","authenticated-orcid":false,"given":"P.","family":"Manca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.G.","family":"Leone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"De Stefano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Nisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Rossini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3864-0719","authenticated-orcid":false,"given":"L.","family":"Salvatore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Maiello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2681-2846","authenticated-orcid":false,"given":"S.","family":"Siena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Troiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"De Vita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Fazio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Martinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Ciardiello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Napolitano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.esmogo.2026.100398_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2024.102683","article-title":"The role of anti-EGFR rechallenge in metastatic colorectal cancer, from available data to future developments: a systematic review","volume":"124","author":"Ciardiello","year":"2024","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"10.1016\/j.esmogo.2026.100398_bib2","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s41571-024-00965-0","article-title":"Late-line options for patients with metastatic colorectal cancer: a review and evidence-based algorithm","volume":"22","author":"Cirac\u00ec","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"issue":"5","key":"10.1016\/j.esmogo.2026.100398_bib3","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/s41571-026-01126-1","article-title":"Evolving roles of liquid biopsy in precision medicine for colorectal cancer: from single-gene analysis to broad genomic profiling","volume":"23","author":"Martini","year":"2026","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"10.1016\/j.esmogo.2026.100398_bib4","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1093\/annonc\/mdy509","article-title":"Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challenge","volume":"30","author":"Parseghian","year":"2019","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.esmogo.2026.100398_bib5","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.5635","article-title":"Anti-EGFR rechallenge in patients with refractory ctDNA RAS\/BRAF wt metastatic colorectal cancer: a nonrandomized controlled trial","volume":"7","author":"Ciardiello","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"1","key":"10.1016\/j.esmogo.2026.100398_bib6","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.annonc.2025.10.002","article-title":"Re-treatment with panitumumab followed by regorafenib versus the reverse sequence in chemorefractory metastatic colorectal cancer patients with RAS and BRAF wild-type circulating tumor DNA: the PARERE study by GONO","volume":"37","author":"Cirac\u00ec","year":"2026","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmogo.2026.100398_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2026.105180","article-title":"Anti-EGFR rechallenge compared with standard of care for patients with ctDNA RAS\/BRAF wild-type chemorefractory metastatic colorectal cancer: a systematic review and meta-analysis","volume":"220","author":"Kuznetsova","year":"2026","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"10.1016\/j.esmogo.2026.100398_bib8","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.annonc.2022.10.003","article-title":"Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Cervantes","year":"2023","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.esmogo.2026.100398_bib9","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1038\/s41591-022-01886-0","article-title":"Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial","volume":"28","author":"Sartore-Bianchi","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.esmogo.2026.100398_bib10","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.852583","article-title":"Liquid biopsy-driven cetuximab rechallenge strategy in molecularly selected metastatic colorectal cancer patients","volume":"12","author":"Mariani","year":"2022","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.esmogo.2026.100398_bib11","first-page":"1","article-title":"Real-world outcomes of anti-EGFR rechallenge guided by liquid biopsy in metastatic colorectal cancer","volume":"33","author":"Roque","year":"2026","journal-title":"GE Port J Gastroenterol"},{"issue":"22","key":"10.1016\/j.esmogo.2026.100398_bib12","doi-asserted-by":"crossref","first-page":"5715","DOI":"10.3390\/cancers13225715","article-title":"Skin toxicity as predictor of survival in refractory patients with RAS wild-type metastatic colorectal cancer treated with cetuximab and avelumab (CAVE) as rechallenge strategy","volume":"13","author":"Ciardiello","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"10","key":"10.1016\/j.esmogo.2026.100398_bib13","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1001\/jamaoncol.2021.2915","article-title":"Cetuximab rechallenge plus avelumab in pretreated patients with RAS wild-type metastatic colorectal cancer: the phase 2 single-arm clinical CAVE trial","volume":"7","author":"Martinelli","year":"2021","journal-title":"JAMA Oncol"},{"issue":"2","key":"10.1016\/j.esmogo.2026.100398_bib14","first-page":"141","article-title":"Final results of the CAVE trial in RAS wild type metastatic colorectal cancer patients treated with cetuximab plus avelumab as rechallenge therapy: neutrophil to lymphocyte ratio predicts survival","volume":"21","author":"Ciardiello","year":"2022","journal-title":"Clin Colorectal Cancer"},{"key":"10.1016\/j.esmogo.2026.100398_bib15","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.940523","article-title":"CAVE-2 (Cetuximab-AVElumab) mCRC: a phase II randomized clinical study of the combination of avelumab plus cetuximab as a rechallenge strategy in pre-treated RAS\/BRAF wild-type mCRC patients","volume":"12","author":"Napolitano","year":"2022","journal-title":"Front Oncol"},{"issue":"7","key":"10.1016\/j.esmogo.2026.100398_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.105491","article-title":"Comprehensive genomic profiling by liquid biopsy in refractory metastatic colorectal cancer patients who are candidate for anti-EGFR rechallenge therapy: findings from the CAVE-2 GOIM trial","volume":"10","author":"Ciardiello","year":"2025","journal-title":"ESMO Open"},{"issue":"5","key":"10.1016\/j.esmogo.2026.100398_bib17","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.annonc.2025.12.014","article-title":"Cetuximab rechallenge in molecularly selected metastatic colorectal cancer: the randomized CAVE-2 GOIM trial","volume":"37","author":"Ciardiello","year":"2026","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.esmogo.2026.100398_bib18","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1002\/cpt.1645","article-title":"Changing body weight-based dosing to a flat dose for avelumab in metastatic Merkel cell and advanced urothelial carcinoma","volume":"107","author":"Novakovic","year":"2020","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.esmogo.2026.100398_bib31","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"9863","key":"10.1016\/j.esmogo.2026.100398_bib19","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0140-6736(12)61900-X","article-title":"Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial","volume":"381","author":"Grothey","year":"2013","journal-title":"Lancet"},{"issue":"10395","key":"10.1016\/j.esmogo.2026.100398_bib20","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0140-6736(23)00772-9","article-title":"Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study","volume":"402","author":"Dasari","year":"2023","journal-title":"Lancet"},{"issue":"18","key":"10.1016\/j.esmogo.2026.100398_bib21","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1056\/NEJMoa2214963","article-title":"Trifluridine-tipiracil and bevacizumab in refractory metastatic colorectal cancer","volume":"388","author":"Prager","year":"2023","journal-title":"N Engl J Med"},{"issue":"suppl 2","key":"10.1016\/j.esmogo.2026.100398_bib22","doi-asserted-by":"crossref","first-page":"S1576","DOI":"10.1016\/j.annonc.2025.09.044","article-title":"LBA33 Circulating tumor (ct) DNA-guided anti-EGFR rechallenge strategy in metastatic colorectal cancer (mCRC): final results of the phase II randomized CITRIC trial","volume":"36","author":"Montagut","year":"2025","journal-title":"Ann Oncol"},{"issue":"suppl 16","key":"10.1016\/j.esmogo.2026.100398_bib23","doi-asserted-by":"crossref","first-page":"3514","DOI":"10.1200\/JCO.2025.43.16_suppl.3514","article-title":"Longitudinal ctDNA monitoring and prediction of anti-EGFR rechallenge outcomes in RAS\/BRAF wild-type metastatic colorectal cancer (mCRC): the REMARRY & PURSUIT trials","volume":"43","author":"Kagawa","year":"2025","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.esmogo.2026.100398_bib24","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1158\/2767-9764.CRC-25-0690","article-title":"Effect of liver metastases on survival in microsatellite-stable metastatic colorectal cancer treated with immune checkpoint inhibitors","volume":"6","author":"Pakvisal","year":"2026","journal-title":"Cancer Res Commun"},{"issue":"9","key":"10.1016\/j.esmogo.2026.100398_bib25","doi-asserted-by":"crossref","first-page":"2558","DOI":"10.1038\/s41591-024-03083-7","article-title":"Botensilimab plus balstilimab in relapsed\/refractory microsatellite stable metastatic colorectal cancer: a phase 1 trial","volume":"30","author":"Bullock","year":"2024","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.esmogo.2026.100398_bib26","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1001\/jamaoncol.2022.7845","article-title":"Regorafenib, ipilimumab, and nivolumab for patients with microsatellite stable colorectal cancer and disease progression with prior chemotherapy: a phase 1 nonrandomized clinical trial","volume":"9","author":"Fakih","year":"2023","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.esmogo.2026.100398_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.113437","article-title":"Immunotherapy response in microsatellite stable metastatic colorectal cancer is influenced by site of metastases","volume":"196","author":"Fakih","year":"2024","journal-title":"Eur J Cancer"},{"issue":"10517","key":"10.1016\/j.esmogo.2026.100398_bib28","doi-asserted-by":"crossref","first-page":"2360","DOI":"10.1016\/S0140-6736(25)02025-2","article-title":"Zanzalintinib plus atezolizumab versus regorafenib in refractory colorectal cancer (STELLAR-303): a randomised, open-label, phase 3 trial","volume":"406","author":"Hecht","year":"2025","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.esmogo.2026.100398_bib29","first-page":"191","article-title":"Retreatment with anti-EGFR antibodies in metastatic colorectal cancer patients: a multi-institutional analysis","volume":"19","author":"Rossini","year":"2020","journal-title":"Clin Colorectal Cancer"},{"issue":"12","key":"10.1016\/j.esmogo.2026.100398_bib30","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1016\/S1470-2045(16)30500-9","article-title":"Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database","volume":"17","author":"Franko","year":"2016","journal-title":"Lancet Oncol"}],"container-title":["ESMO Gastrointestinal Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949819826000981?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949819826000981?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T22:37:08Z","timestamp":1792535828000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2949819826000981"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":31,"alternative-id":["S2949819826000981"],"URL":"https:\/\/doi.org\/10.1016\/j.esmogo.2026.100398","relation":{},"ISSN":["2949-8198"],"issn-type":[{"value":"2949-8198","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Predictive biomarkers for cetuximab-based rechallenge therapy in metastatic colorectal cancer: a pooled analysis of the CAVE and CAVE-2 GOIM studies","name":"articletitle","label":"Article Title"},{"value":"ESMO Gastrointestinal Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmogo.2026.100398","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100398"}}